文献速递性腺与生殖内分泌

微粒化黄体酮改善睡眠:随机对照试验的系统综述与荟萃分析

Efficacy of Micronized Progesterone for Sleep: A Systematic Review and Meta-analysis of Randomized Controlled Trial Data.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该系统综述与荟萃分析纳入9项随机对照试验共388名参与者,多数为绝经后女性,评估微粒化黄体酮对睡眠结局的影响。与安慰剂相比,微粒化黄体酮在多项多导睡眠图参数上有所改善,但研究间不一致;荟萃分析显示其改善入睡潜伏期,而对总睡眠时间和睡眠效率无显著影响。自我报告的睡眠结局在多数试验中改善。

要点

  • 微粒化黄体酮可能改善绝经后女性入睡潜伏期,但总睡眠时间和睡眠效率无显著改善。
  • 多数试验自我报告的睡眠结局改善,但多导睡眠图结果不一致。
  • 部分研究同时使用雌二醇或血管舒缩症状改善,限制结论。

核心结论

  • 微粒化黄体酮在随机对照试验中改善多种睡眠结局,主要见于绝经后女性研究。
  • 需要更大样本研究评估微粒化黄体酮单药治疗对睡眠的疗效。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase、PsycInfo和Cochrane Central Register of Controlled Trials截至2020年3月31日的随机对照试验。
  • 纳入9项随机对照试验共388名参与者,另发现1项未发表试验。
  • 8项试验纳入绝经后女性,采用随机效应模型进行定量分析。

主要发现

  • 与安慰剂相比,微粒化黄体酮改善多导睡眠图测量的总睡眠时间和入睡潜伏期等参数,但研究间不一致。
  • 多数试验自我报告的睡眠结局改善。

临床怎么用

  • 对于绝经后女性睡眠障碍,微粒化黄体酮可能作为改善入睡潜伏期的选择,但需考虑证据不一致性。
  • 同时使用雌二醇或血管舒缩症状改善可能影响对睡眠结局的解读。

局限性

  • 研究间结果不一致,部分研究同时使用雌二醇和血管舒缩症状改善限制结论。
  • 多数试验纳入绝经后女性,其他人群证据有限。
  • 需要更大样本研究使用多导睡眠图或验证问卷评估微粒化黄体酮单药治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Preclinical data has shown progesterone metabolites improve sleep parameters through positive allosteric modulation of the γ-aminobutyric acid type A receptor. We undertook a systematic review and meta-analysis of randomized controlled trials to assess micronized progesterone treatment on sleep outcomes. EVIDENCE ACQUISITION: Using preferred reporting items for systematic review and meta-analysis guidelines, we searched MEDLINE, Embase, PsycInfo, and the Cochrane Central Register of Controlled Trials for randomized controlled trials of micronized progesterone treatment on sleep outcomes up to March 31, 2020. This study is registered with the International Prospective Register of Systematic Reviews, number CRD42020165981. A random effects model was used for quantitative analysis. EVIDENCE SYNTHESIS: Our search strategy retrieved 9 randomized controlled trials comprising 388 participants. One additional unpublished trial was found. Eight trials enrolled postmenopausal women. Compared with placebo, micronized progesterone improved various sleep parameters as measured by polysomnography, including total sleep time and sleep onset latency, though studies were inconsistent. Meta-analysis of 4 trials favored micronized progesterone for sleep onset latency (effect size, 7.10; confidence interval [CI] 1.30, 12.91) but not total sleep time (effect size, 20.72; CI -0.16, 41.59) or sleep efficiency (effect size, 1.31; CI -2.09, 4.70). Self-reported sleep outcomes improved in most trials. Concomitant estradiol administration and improvement in vasomotor symptoms limit conclusions in some studies. CONCLUSIONS: Micronized progesterone improves various sleep outcomes in randomized controlled trials, predominantly in studies enrolling postmenopausal women. Further research could evaluate the efficacy of micronized progesterone monotherapy using polysomnography or validated questionnaires in larger cohorts.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Nolan BJ, Liang B, Cheung AS, et al. Efficacy of Micronized Progesterone for Sleep: A Systematic Review and Meta-analysis of Randomized Controlled Trial Data. J Clin Endocrinol Metab. 2021. PMID: 33245776. doi:10.1210/clinem/dgaa873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。